Which has stronger earnings and valuation, KARD or KMDA?

Kamada has higher revenue and earnings than Kardigan. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A N/A N/A N/A Kamada $180.46M 2.64 $20.20M $0.38 21.82

Is KARD or KMDA more profitable?

Kamada has a net margin of 11.60% compared to Kardigan's net margin of 0.00%. Kamada's return on equity of 8.37% beat Kardigan's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Kamada 11.60% 8.37% 5.85%

Which has preferable earnings & valuation, KMDA or IMCR?

Kamada has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.64 $20.20M $0.38 21.82 Immunocore $430.78M 4.38 -$35.51M -$0.37 N/A

Is KMDA or IMCR more profitable?

Kamada has a net margin of 11.60% compared to Immunocore's net margin of -4.20%. Kamada's return on equity of 8.37% beat Immunocore's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Immunocore -4.20% -4.54% -1.66%

Which has better earnings & valuation, KMDA or SEPN?

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kamada $180.46M 2.64 $20.20M $0.38 21.82 Septerna $98.88M 18.37 -$48.88M -$0.54 N/A

Is KMDA or SEPN more profitable?

Kamada has a net margin of 11.60% compared to Septerna's net margin of -24.51%. Kamada's return on equity of 8.37% beat Septerna's return on equity. Company Net Margins Return on Equity Return on Assets Kamada 11.60% 8.37% 5.85% Septerna -24.51% -9.57% -6.28%

Kamada (KMDA) Competitors

$8.29 +0.03 (+0.36%)

As of 08/28/2026 04:00 PM Eastern

Compare

KMDA vs. KARD, LKFT, DMRA, IMCR, and SEPN

Should you buy Kamada stock or one of its competitors? Kamada's main competitors and comparable companies include Kardigan (KARD), Lakefront Biotherapeutics American Depositary Shares (LKFT), Damora Therapeutics, Inc. Common Stock (DMRA), Immunocore (IMCR), and Septerna (SEPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kamada compare to Kardigan?

Kardigan (NASDAQ:KARD) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Kardigan had 4 more articles in the media than Kamada. MarketBeat recorded 5 mentions for Kardigan and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Kardigan's score of 0.14 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Kardigan	Neutral
Kamada	Very Positive

Kamada has higher revenue and earnings than Kardigan.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	N/A	N/A	N/A
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Kamada has a net margin of 11.60% compared to Kardigan's net margin of 0.00%. Kamada's return on equity of 8.37% beat Kardigan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Kamada	11.60%	8.37%	5.85%

Kardigan presently has a consensus target price of $42.25, suggesting a potential upside of 111.04%. Kamada has a consensus target price of $13.00, suggesting a potential upside of 56.82%. Given Kardigan's higher probable upside, analysts plainly believe Kardigan is more favorable than Kamada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Kardigan on 8 of the 11 factors compared between the two stocks.

How does Kamada compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kamada. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$990.57M	1.92	$363.05M	-$1.41	N/A
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Kamada. MarketBeat recorded 4 mentions for Lakefront Biotherapeutics American Depositary Shares and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.47 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	Neutral
Kamada	Very Positive

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. Comparatively, 20.4% of Kamada shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Comparatively, 36.1% of Kamada shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Kamada has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Kamada has a net margin of 11.60% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Kamada's return on equity of 8.37% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Kamada	11.60%	8.37%	5.85%

Lakefront Biotherapeutics American Depositary Shares currently has a consensus target price of $30.67, suggesting a potential upside of 6.19%. Kamada has a consensus target price of $13.00, suggesting a potential upside of 56.82%. Given Kamada's stronger consensus rating and higher probable upside, analysts plainly believe Kamada is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Kamada beats Lakefront Biotherapeutics American Depositary Shares on 12 of the 17 factors compared between the two stocks.

How does Kamada compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Kamada (NASDAQ:KMDA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 51.72%. Kamada has a consensus price target of $13.00, suggesting a potential upside of 56.82%. Given Kamada's higher probable upside, analysts clearly believe Kamada is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Kamada has a net margin of 11.60% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Kamada's return on equity of 8.37% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-176.39%	-77.86%
Kamada	11.60%	8.37%	5.85%

Kamada has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$3.37	N/A
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Damora Therapeutics, Inc. Common Stock had 3 more articles in the media than Kamada. MarketBeat recorded 4 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Damora Therapeutics, Inc. Common Stock's score of 1.30 indicating that Kamada is being referred to more favorably in the news media.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Positive
Kamada	Very Positive

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market. Comparatively, Kamada has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Summary

Kamada beats Damora Therapeutics, Inc. Common Stock on 11 of the 15 factors compared between the two stocks.

How does Kamada compare to Immunocore?

Kamada (NASDAQ:KMDA) and Immunocore (NASDAQ:IMCR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 36.1% of Kamada shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kamada has a net margin of 11.60% compared to Immunocore's net margin of -4.20%. Kamada's return on equity of 8.37% beat Immunocore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Immunocore	-4.20%	-4.54%	-1.66%

Kamada presently has a consensus target price of $13.00, indicating a potential upside of 56.82%. Immunocore has a consensus target price of $56.38, indicating a potential upside of 53.95%. Given Kamada's stronger consensus rating and higher probable upside, research analysts clearly believe Kamada is more favorable than Immunocore.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunocore	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.69

Kamada has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Immunocore has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

In the previous week, Immunocore had 5 more articles in the media than Kamada. MarketBeat recorded 6 mentions for Immunocore and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Immunocore's score of 1.00 indicating that Kamada is being referred to more favorably in the media.

Company	Overall Sentiment
Kamada	Very Positive
Immunocore	Positive

Kamada has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82
Immunocore	$430.78M	4.38	-$35.51M	-$0.37	N/A

Summary

Kamada beats Immunocore on 11 of the 17 factors compared between the two stocks.

How does Kamada compare to Septerna?

Kamada (NASDAQ:KMDA) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Septerna had 8 more articles in the media than Kamada. MarketBeat recorded 9 mentions for Septerna and 1 mentions for Kamada. Kamada's average media sentiment score of 1.89 beat Septerna's score of 1.13 indicating that Kamada is being referred to more favorably in the media.

Company	Overall Sentiment
Kamada	Very Positive
Septerna	Positive

Kamada has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kamada	$180.46M	2.64	$20.20M	$0.38	21.82
Septerna	$98.88M	18.37	-$48.88M	-$0.54	N/A

Kamada presently has a consensus target price of $13.00, suggesting a potential upside of 56.82%. Septerna has a consensus target price of $52.44, suggesting a potential upside of 34.78%. Given Kamada's stronger consensus rating and higher possible upside, analysts clearly believe Kamada is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Kamada has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its stock price is 129% more volatile than the broader market.

Kamada has a net margin of 11.60% compared to Septerna's net margin of -24.51%. Kamada's return on equity of 8.37% beat Septerna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kamada	11.60%	8.37%	5.85%
Septerna	-24.51%	-9.57%	-6.28%

Summary

Kamada beats Septerna on 12 of the 17 factors compared between the two stocks.

Get Kamada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KMDA vs. The Competition

Export

Metric	Kamada	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$476.72M	$3.93B	$7.20B	$12.90B
Dividend Yield	1.54%	3.61%	2.54%	11.28%
P/E Ratio	21.82	11.62	273.16	25.45
Price / Sales	2.64	1,295.87	605.06	76.64
Price / Cash	13.58	106.39	76.74	53.00
Price / Book	1.77	16.53	12.98	6.14
Net Income	$20.20M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.61%	-0.31%	0.13%	-0.80%
1 Month Performance	16.76%	9.80%	7.08%	4.13%
1 Year Performance	19.80%	55.66%	24.67%	15.17%

Kamada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KMDA Kamada	4.9333 of 5 stars	$8.29 +0.4%	$13.00 +56.8%	+19.8%	$476.72M	$180.46M	21.82	360	Positive News
KARD Kardigan	3.6573 of 5 stars	$20.85 +1.0%	$42.25 +102.6%	N/A	$1.95B	N/A	N/A	N/A	News Coverage Analyst Forecast
LKFT Lakefront Biotherapeutics American Depositary Shares	1.325 of 5 stars	$29.58 +1.9%	$30.67 +3.7%	-8.1%	$1.95B	$1.26B	N/A	1,310	Analyst Upgrade
DMRA Damora Therapeutics, Inc. Common Stock	2.8826 of 5 stars	$31.09 +2.6%	$44.00 +41.5%	+813.1%	$1.92B	N/A	N/A	40	Positive News
IMCR Immunocore	3.6573 of 5 stars	$36.95 +0.9%	$56.38 +52.6%	+13.7%	$1.90B	$400.02M	N/A	320	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KMDA) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kamada (KMDA) Competitors